Compare IDEXX Laboratories, Inc. (IDXX) vs Prologis Inc (PLD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Prologis Inc — how do they compare? IDEXX Laboratories, Inc. trades at $552.09 (market cap $44.48B), while Prologis Inc trades at $148.98 (market cap $137.50B). The key difference: Prologis Inc is far larger — about 3.1× IDEXX Laboratories, Inc.'s market cap, and Prologis Inc pays a 2.9% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| IDXX | PLD | |
|---|---|---|
Market Cap | $44.48B | $137.50B |
Sector | Health | Real Estate |
52-Week High | $766.68 | $149.96 |
52-Week Low | $520.87 | $104.08 |
Enterprise Value | $45.38B | $172.18B |
Dividend Yield | — | 2.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDXX trades at $563.79, down 0.64% today but maintains strong fundamental momentum with consistent earnings beats and robust profitability. The stock shows bullish technical signals with support at $563 and resistance at $572, while valuation metrics remain elevated. Recent Q1 2026 results exceeded expectations with EPS of $3.47 versus $3.41 estimates, supporting the company's leadership in veterinary diagnostics.
Outlook remains positive given strong analyst support (59% buy ratings) and innovation pipeline, though premium valuations and competitive pressures present risks. Revenue growth trajectory and expanding margins provide fundamental support for continued upside potential in the pet healthcare sector.
Prologis (PLD) trades at $147.17, down 1.7% on the day, with strong technical momentum showing bullish moving averages and key support at $146. The company demonstrates robust fundamentals with consistent earnings beats, including Q2 2026 EPS of $1.13 beating expectations of $0.747, and maintains healthy profitability with 41.54% net income margin. Recent news highlights Prologis' aggressive expansion strategy with multiple takeover bids for SEGRO valued at $18.2 billion.
The outlook remains positive with analyst consensus at Buy (57% of coverage) and $156.56 price target representing 6.4% upside. Key opportunities include data center expansion and record leasing activity, while risks involve elevated valuation multiples (P/E 33.36) and increasing debt levels (debt-to-asset ratio rising to 37.2% in 2025).
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Prologis Inc
Prologis was formed by the June 2011 merger of AMB Property and Prologis Trust. The company develops, acquires, and operates around 1 billion square feet of high-quality industrial and logistics facilities across the globe. The company also has a strategic capital business segment that has around $70 billion of third-party AUM. The company is organized into four global divisions (Americas, Europe, Asia, and other Americas) and operates as a real estate investment trust.
Read more on PLD →
